Telbivudine versus lamivudine in patients with chronic hepatitis B.

CL, Lai; E, Gane; YF, Liaw; CW, Hsu; S, Thongsawat; Y, Wang; Y, Chen; EJ, Heathcote; J, Rasenack; N, Bzowej; NV, Naoumov; Bisceglie AM, Di; S, Zeuzem; YM, Moon; Z, Goodman; G, Chao; BF, Constance; NA, Brown

doi:10.1056/nejmoa066422

Public

Telbivudine versus lamivudine in patients with chronic hepatitis B.

Shared by NobleBlocks on Dec 1, 2007 • 12:00 AM UTC

Authors:

Lai CL

Gane E

Liaw YF

Abstract

Background Reducing hepatitis B virus (HBV) replication to minimal levels is emerging as a key therapeutic goal for chronic hepatitis B.Methods In this double-blind, phase 3 trial, 1370 patients with chronic hepatitis B were randomly assigned to receive 600 mg of telbivudine or 100 mg of lamivudine ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!